Notiabolfen Xl (Quetiapine)

Quetiapine, the active ingredient in Notiabolfen Xl, is an atypical antipsychotic presented as an oral dosage form for oral use. It is prescribed for the management of schizophrenia, bipolar disorder and as an adjunct in major depressive disorder in adult patients.

GNH USA supplies Notiabolfen Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive regulatory support and timely delivery across multiple continents.

Quetiapine is used to treat several psychiatric disorders by modulating neurotransmitter activity.

Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. Bipolar disorder (manic episodes): stabilizes mood and decreases manic symptoms. Bipolar disorder (depressive episodes): alleviates depressive symptoms when used as part of maintenance therapy. Adjunctive treatment of major depressive disorder: enhances antidepressant response in patients with inadequate improvement.

Quetiapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to oral discomfort. - Weight gain: increase in body weight over time. - Constipation: difficulty passing stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Elevated cholesterol: rise in blood lipid levels.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, especially of the face. - Severe hypotension: marked drop in blood pressure causing faintness. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Blood dyscrasias: agranulocytosis or severe leukopenia. - Pancreatitis: inflammation of the pancreas.

When prescribing quetiapine, clinicians should consider several safety measures and monitoring requirements.

Assess cardiovascular status: monitor blood pressure and heart rate, especially at treatment initiation. Screen for metabolic risk: evaluate weight, glucose and lipid profile periodically. Review psychiatric history: consider risk of suicidal ideation, especially in young adults. Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. Pregnancy and lactation: weigh potential benefits against unknown risks; consult obstetric guidance. Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Quetiapine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, risking toxicity. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Antihypertensive agents: enhanced hypotensive effect leading to dizziness.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine concentrations, decreasing efficacy. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Lithium: combined use may increase risk of neurotoxicity.